MicroRNA-664 suppresses the growth of cervical cancer cells via targeting c-Kit

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–156.11668491
   PubMed Web of Science ®Google Scholar
• Granados Lopez AJ, Lopez JA. Multistep model of cervical cancer: participation of miRNAs and coding genes. Int J Mol Sci. 2014;15(9):15700–15733. doi:10.3390/ijms15091570025192291
   PubMed Web of Science ®Google Scholar
• de Freitas AC, Gomes Leitao Mda C, Coimbra EC. Prospects of molecularly-targeted therapies for cervical cancer treatment. Curr Drug Targets. 2015;16(1):77–91.25479546
   PubMed Web of Science ®Google Scholar
• Shishodia G, Verma G, Das BC, Bharti AC. miRNA as viral transcription tuners in HPV-mediated cervical carcinogenesis. Front Biosci (Schol Ed). 2018;10:21–47.28930517
   PubMedGoogle Scholar
• Filippeschi M, Moncini I, Bianchi B, Florio P. What kind of surgery for cervical carcinoma? G Chir. 2012;33(4):139–146.22668535
   PubMedGoogle Scholar
• Morales S, Monzo M, Navarro A. Epigenetic regulation mechanisms of microRNA expression. Biomol Concepts. 2017;8(5–6):203–212. doi:10.1515/bmc-2017-002429161231
   PubMedGoogle Scholar
• McAnena P, Tanriverdi K, Curran C, et al. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer. BMC Cancer. 2019;19(1):436. doi:10.1186/s12885-019-5636-y31077182
   PubMed Web of Science ®Google Scholar
• Drusco A, Croce CM. MicroRNAs and cancer: a long story for short RNAs. Adv Cancer Res. 2017;135:1–24. doi:10.1016/bs.acr.2017.06.00528882219
   PubMed Web of Science ®Google Scholar
• Fang Z, Rajewsky N. The impact of miRNA target sites in coding sequences and in 3’UTRs. PLoS One. 2011;6(3):e18067. doi:10.1371/journal.pone.001806721445367
   PubMed Web of Science ®Google Scholar
• Xian X, Tang L, Wu C, Huang L. miR-23b-3p and miR-130a-5p affect cell growth, migration and invasion by targeting CB1R via the Wnt/beta-catenin signaling pathway in gastric carcinoma. Onco Targets Ther. 2018;11:7503–7512. doi:10.2147/OTT.S18170630498363
   PubMed Web of Science ®Google Scholar
• Kan X, Sun Y, Lu J, et al. Coinhibition of miRNA21 and miRNA221 induces apoptosis by enhancing the p53mediated expression of proapoptotic miRNAs in laryngeal squamous cell carcinoma. Mol Med Rep. 2016;13(5):4315–4320. doi:10.3892/mmr.2016.504827035337
   PubMed Web of Science ®Google Scholar
• Yin XZ, Zhao DM, Zhang GX, Liu L. Effect of miRNA-203 on cervical cancer cells and its underlying mechanism. Genet Mol Res. 2016;15(3). doi:10.4238/gmr.15038680
   Google Scholar
• Li C, Jia L, Yu Y, Jin L. Lactic acid induced microRNA-744 enhances motility of SiHa cervical cancer cells through targeting ARHGAP5. Chem Biol Interact. 2018;298:86–95. doi:10.1016/j.cbi.2018.10.02730423314
   PubMed Web of Science ®Google Scholar
• Fiala O, Pitule P, Hosek P, et al. The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol. 2017;39(7):1010428317709283. doi:10.1177/101042831770928328714375
   PubMedGoogle Scholar
• Lee BP, Buric I, George-Pandeth A, et al. MicroRNAs miR-203-3p, miR-664-3p and miR-708-5p are associated with median strain lifespan in mice. Sci Rep. 2017;7:44620. doi:10.1038/srep4462028304372
   PubMed Web of Science ®Google Scholar
• Zhu X, Ju S, Yuan F, et al. microRNA-664 enhances proliferation, migration and invasion of lung cancer cells. Exp Ther Med. 2017;13(6):3555–3562. doi:10.3892/etm.2017.443328588679
   PubMed Web of Science ®Google Scholar
• Bao Y, Chen B, Wu Q, et al. Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7. Clin Exp Med. 2017;17(1):51–58. doi:10.1007/s10238-015-0398-626515813
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu H, Wang X, Chen L. Up-regulation of microRNA-664 inhibits cell growth and increases cisplatin sensitivity in cervical cancer. Int J Clin Exp Med. 2015;8(10):18123–18129.26770409
   PubMed Web of Science ®Google Scholar
• Majumder S, Brown K, Qiu FH, Besmer P. c-kit protein, a transmembrane kinase: identification in tissues and characterization. Mol Cell Biol. 1988;8(11):4896–4903. doi:10.1128/mcb.8.11.48962463468
   PubMed Web of Science ®Google Scholar
• Zou T, Gao L, Zeng Y, et al. Organoid-derived C-Kit(+)/SSEA4(-) human retinal progenitor cells promote a protective retinal microenvironment during transplantation in rodents. Nat Commun. 2019;10(1):1205. doi:10.1038/s41467-019-08961-030872578
   PubMed Web of Science ®Google Scholar
• Stankov K, Popovic S, Mikov M. C-KIT signaling in cancer treatment. Curr Pharm Des. 2014;20(17):2849–2880.23944364
   PubMed Web of Science ®Google Scholar
• Kellner J, Wallace C, Liu B, Li Z. Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s. JCI Insight. 2019;4(7). doi:10.1172/jci.insight.122686
   PubMed Web of Science ®Google Scholar
• Aguilar C, Aguilar C, Lopez-Marure R, Jimenez-Sanchez A, Rocha-Zavaleta L. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2. Mol Med Rep. 2014;9(5):1895–1902. doi:10.3892/mmr.2014.204424626629
   PubMed Web of Science ®Google Scholar
• Li XY, Wang X. The role of human cervical cancer oncogene in cancer progression. Int J Clin Exp Med. 2015;8(6):8363–8368.26309489
   PubMed Web of Science ®Google Scholar
• Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008;27(45):5959–5974. doi:10.1038/onc.2008.27418836476
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12. doi:10.1016/j.ydbio.2006.08.02816989803
   PubMed Web of Science ®Google Scholar
• Ding Z, Jian S, Peng X, et al. Loss of MiR-664 expression enhances cutaneous malignant melanoma proliferation by upregulating PLP2. Medicine. 2015;94(33):e1327. doi:10.1097/MD.000000000000087426287415
   PubMed Web of Science ®Google Scholar
• Zhang YX, Qin LL, Yang SY. Down-regulation of miR-664 in cervical cancer is associated with lower overall survival. Eur Rev Med Pharmacol Sci. 2016;20(9):1740–1744.27212165
   PubMed Web of Science ®Google Scholar
• Lu Y, Govindan R, Wang L, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis. 2012;33(5):1046–1054. doi:10.1093/carcin/bgs10022331473
   PubMed Web of Science ®Google Scholar
• Chen B, Bao Y, Chen X, et al. Mir-664 promotes osteosarcoma cells proliferation via downregulating of FOXO4. Biomed Pharmacother. 2015;75:1–7. doi:10.1016/j.biopha.2015.08.01226463624
   PubMed Web of Science ®Google Scholar
• Caceres-Cortes JR. A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490. Anticancer Agents Med Chem. 2008;8(7):717–722.18855573
   PubMed Web of Science ®Google Scholar
• Franceschi S, Lessi F, Panebianco F, et al. Loss of c-KIT expression in thyroid cancer cells. PLoS One. 2017;12(3):e0173913. doi:10.1371/journal.pone.017391328301608
   PubMed Web of Science ®Google Scholar
• Chau WK, Ip CK, Mak AS, Lai HC, Wong AS. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene. 2013;32(22):2767–2781. doi:10.1038/onc.2012.29022797058
   PubMed Web of Science ®Google Scholar
• Kajiguchi T, Lee S, Lee MJ, Trepel JB, Neckers L. KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. Leuk Res. 2008;32(5):761–770. doi:10.1016/j.leukres.2007.08.02317949810
   PubMed Web of Science ®Google Scholar